515 results about "Proliferative disease" patented technology

The present disclosure is related to dual payload antibody drug conjugates comprising at least one topoisomerase inhibitor and at least one DNA Damage Response (DDR) inhibitor, pharmaceutical compositions thereof, and the use of the antibody drug conjugates and compositions thereof for the treatment of diseases and disorders, including proliferative diseases.

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The present disclosure is related to dual payload immunostimulatory antibody drug conjugates comprising at least STING agonist and at least one cytotoxic agent, pharmaceutical compositions thereof, and the use of the dual payload immunostimulatory antibody drug conjugates and compositions thereof for the treatment of diseases and disorders, including proliferative diseases.

Disclosed are compounds of Formula (I): # imgabs0 # or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, X, Y, Z and W are as defined herein. The compounds are inhibitors of, for example, WRN helicase and are useful in the treatment of proliferative diseases such as cancer.

Described herein are compounds useful in the treatment of TYK2 mediated diseases. In some embodiments, the TYK2-mediated disease is an autoimmune disease, an inflammatory disease, a proliferative disease, an endocrine disease, a neurological disease, or a disease associated with transplantation.

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.

The invention relates to the field of 26S proteasome inhibition and modulation by niclosamide and to a method for treating diseases related to increased proliferation, immune system, inflammation and neurodegenerative disorders by inhibition and modulation of the 26S proteasome in living cells, and to a niclosamide-containing compound for use in this treatment.

The present invention discloses salts of a Compound 1:useful in the prophylaxis and / or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and / or disruption of cartilage homeostasis, congenital cartilage malformations, and / or diseases associated with hypersecretion of IL6 or interferons.

Disclosed are compounds of Formula (I): # imgabs0 # or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R2a, R3, R3a, m, n and W are as defined herein. The compounds are inhibitors of, for example, WRN helicase and are useful in the treatment of proliferative diseases such as cancer.

The invention relates to a cucurbituril compound and medical application thereof. Specifically, the invention relates to a compound as shown in a formula (I) and a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the compound and application thereof as a therapeutic agent, especially application in treatment or prevention of proliferative diseases, cardiovascular related diseases or hematologic cancers, use in reversing drug-induced neuromuscular block and / or anesthesia. I) # imgabs0 #

Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and / or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and / or adaptive immune response), and are useful in treating and / or preventing a disease, as adjuvants in a vaccine for the disease. (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula I below, and the use of that inhibitor for treating a proliferative disease:

A compound for degrading a Wee1 protein kinase or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of proliferative diseases.

A method for treating proliferative diseases such as cancer in a subject by a combination therapy, which includes administering to the subject a pharmaceutical composition including a benzenesulfonamide derivative such as p-Toluenesulfonamide and at least one other therapeutic agents in a different classification of anticancer agents.

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More specifically, the present invention provides particles comprising MOFs, optionally at least one targeting moiety, and at least one short-lived radionuclide; compositions comprising the particles; the particles or compositions for use as imaging agents; the particles or compositions for use in methods for diagnosing proliferative diseases; the particles or compositions for use in methods for diagnosing chronic inflammatory diseases; and kits comprising particles comprising MOFs, optionally a targeting moiety, and a short-lived radionuclide cation.

Disclosed are compounds of Formula (I): (I) or stereoisomers, tautomers, or salts thereof, wherein R is defined herein. Also disclosed are methods of using such compounds to decrease the levels of Ikaros protein, Helios protein, Aiolos protein, and Eos protein; and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

The present disclosure provides a novel bifunctional compound that degrades EGFR, pharmaceutical compositions containing the compound, methods of preparation, and uses of the compounds of the disclosure to treat cell proliferative diseases, such as cancer.

The invention relates to a compound used as a CDK4 kinase inhibitor and application thereof. Specifically, the compound disclosed by the invention has a structure as shown in a formula II, and the definitions of all groups and substituent groups are described in the specification. The compound provided by the invention can be used as an inhibitor of cyclin-dependent kinase (CDK), is used for treating or preventing proliferative diseases (such as cancers), and is particularly used for regulating and treating related diseases caused by abnormal activity of the cyclin-dependent kinase (CDK). # imgabs0 #

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of the PI3Kα enzyme using the compounds and compositions of the present disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Kα signaling using the compounds and compositions of the present disclosure. Inhibitors of PI3Kα are considered to be particularly valuable in the treatment of proliferative diseases and other disorders. A plurality of inhibitors of PI3K (for example, taselisib, alpelisib, buparlisib, etc.) have been developed, but these molecules inhibit multiple class 1A PI3K isoforms.

The present invention relates to an antibody-drug conjugate, wherein the antibody specifically binds to the folate receptor a and the drug is preferably selected from among cytotoxic drugs. Such antibody-drug conjugates are particularly useful in the treatment of proliferative diseases, including cancers such as ovarian cancer, breast cancer and non-small cell lung cancer.

The present invention relates to a benzo five-membered heterocyclic derivative and a use thereof. Specifically, disclosed is a compound having a structure as shown in formula (I) or formula (II), the definitions of the groups and substituents being as set forth in the description. Also disclosed is a use of the compound in treating or preventing diseases related to PARG activity, in particular proliferative diseases (such as cancer).

The present invention relates to compounds having cyclin-dependent kinase (CDK)-inhibitory functions and / or pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and / or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing such compounds.

The present invention relates to MOFs for radiotherapy. More specifically, the present invention provides: a particle comprising an MOF, optionally at least one targeting moiety, and at least one beta-emitting radionuclide; a composition comprising the particles; said particles or composition for use as a medicament; said particles or compositions for use in a method of treating a proliferative disease; and a kit comprising a particle comprising an MOF, optionally a targeting moiety, and a beta-emitting radionuclide.

The present invention relates to the use of small molecule compounds that allosterically inhibit ALC1 (CHD1L), in particular two classes allosteric inhibitors of ALC1 (CHD1L), of Formula (I) and Formula (II), that show a potentiating, preferably additive effect in the treatment of proliferative disease when combined with several classes of cancer drugs, namely inhibitors of Topoisomerase I, Topoisomerase II, ATM, ATR, Wee1, BRD, and MEK, or when combined with mitomycin C, paclitaxel, with ionizing radiation, or with an antibody drug conjugate with a tumor specific antibody conjugated to a TOP1 inhibitor. Furthermore, the present invention relates to said inhibitors of ALC1 of Formula (II) that show a synergistic effect in the treatment of pancreatic cancer or fallopian tube cancer when combined with a PARP inhibitor (Poly(ADP-ribose)-Polymerase inhibitor (PARPi)). By being synergistic with the function of said cancer drugs, said ALC1 inhibitors, in particular those of Formula (I) and Formula (II), potentiate the cancer cell killing properties of the aforementioned cancer drugs, in particular enabling therapeutic approaches where any of the aforementioned inhibitors is already used as part of the standard of care.

The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula (I) below, and the use of that inhibitor for treating a proliferative disease.

Provided are serum-resistant vaccinia extracellular enveloped viruses (EEV), methods of producing serum-resistant EEVs, and modified EEVs for systemic oncolytic viral therapy. Provided herein are methods to modify vaccinia viruses to produce serum resistant EEVs for systemic oncolytic viral therapy. Compositions containing serum resistant EEVs and methods of treating cancers and other proliferative diseases are provided.

The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof. Also provided are methods (or uses) and kits involving the compounds or pharmaceutically acceptable compositions containing them for treating or preventing a disease (e.g., a proliferative disease such as cancer) in a subject. Administration of a compound or pharmaceutical composition described herein is expected to inhibit cyclin-dependent kinase 7 (CDK7), and thereby, induce apoptosis in tumor cells in the subject.

A camptothecin compound and a conjugate thereof, or a tautomer thereof, an enantiomer thereof, a diastereomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, a preparation method therefor, and use thereof. The compound and the conjugate can be used for treating proliferative diseases related to abnormal cell activity.